- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02274636
Study of a Dietary Supplement for Reflux During Sleep (SXDSFRS)
This research study is a randomized, controlled study developed to test how well a dry mouth product that contains xylitol affects some of the symptoms of gastroesophageal reflux disease (GERD. Individuals who experience symptoms of gastro esophageal reflux disease (GERD) and who are accepted into the study will be asked to report on the frequency and severity of several symptoms specific to the condition that occur during sleep. The study is composed of two phases:
Phase one involves collection of baseline information for two weeks. Phase two is the intervention phase of the study. In this phase of the study, each subject will be randomly assigned (like flipping a coin) to use either "the product" of interest or a different dry mouth product for two weeks.
Study Overview
Detailed Description
The study is composed of two phases:
Phase one involves collection of baseline information for two weeks. Phase two is the intervention phase of the study. In this phase of the study, each subject will be randomly assigned (like flipping a coin) to use either "the product" of interest or a different dry mouth product for two weeks.
Phase 1
This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights). You will also be asked to rate the relative severity of some of the symptoms. The information collected during this initial phase of the study will then be used to establish baseline values for the symptoms of interest and determine your eligibility for the intervention phase (phase 2) of the study.
Phase 2
In the second phase of the study, you will be given either enough gel or enough discs to use for 14 days (the duration of the second phase of the study). If you are given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If you are given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). You will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as you did during phase 1 of the study.
During phases 1 and 2 of the study, you will be asked to continue taking any previously prescribed medication or over-the-counter preparations that you normally take for reflux and to maintain your regular dietary habits. However, you should not take any dry mouth remedy other than those supplied by the research coordinator just before bed.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jeff A Burgess, DMD MSD
- Phone Number: 206 450 2640
- Email: oral.care.research.assoc@gmail.com
Study Contact Backup
- Name: Peter F van der Ven, DDS PhD
- Phone Number: 253 874 2583
- Email: ven@seanet.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A medical diagnosis of GERD
- Awakening with a taste of refluxed stomach acid in the mouth
- Heartburn during sleep
- Voice hoarseness upon awakening
- Antacid use at night
- Dry mouth at bedtime or during the night
- Experience difficulty chewing, swallowing, and speaking because of dry mouth
Exclusion Criteria:
- Under 18
Prior history of any of these conditions:
- coronary artery disease
- gallbladder disease
- gastric or esophageal cancer
- peptic ulcer disease
- esophagitis, whether eosinophilic, infectious, or pill based
- esophageal motility disorders
- A history of thoracic, esophageal, or gastric surgery
- No medical examination in the prior year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Data collection
This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep.
Phase 1 will occur over 14 days (and nights).
|
|
Active Comparator: Intervention
In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study).
If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed.
If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions).
Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
|
A comparison between discs and gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in symptoms associated with GERD
Time Frame: two weeks
|
Email questionnaire containing 9 questions of interest
|
two weeks
|
Collaborators and Investigators
Investigators
- Study Director: Jeff A Burgess, DDS MSD, Oral Care Research Associates, Seattle
Publications and helpful links
General Publications
- Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56. doi: 10.1016/s0016-5085(97)70025-8.
- Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. doi: 10.1038/ajg.2012.444. Epub 2013 Feb 19. No abstract available. Erratum In: Am J Gastroenterol. 2013 Oct;108(10):1672.
- Ranjitkar S, Smales RJ, Kaidonis JA. Oral manifestations of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012 Jan;27(1):21-7. doi: 10.1111/j.1440-1746.2011.06945.x.
- Eckley CA, Rios Lda S, Rizzo LV. Salivary egf concentration in adults with reflux chronic laryngitis before and after treatment: preliminary results. Braz J Otorhinolaryngol. 2007 Mar-Apr;73(2):156-60. doi: 10.1016/s1808-8694(15)31060-0.
- Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009 Apr;7(4):372-8; quiz 367. doi: 10.1016/j.cgh.2008.11.021. Epub 2008 Dec 3.
- Burgess J, Lee P. XyliMelts time-release adhering discs for night-time oral dryness. Int J Dent Hyg. 2012 May;10(2):118-21. doi: 10.1111/j.1601-5037.2011.00532.x. Epub 2011 Oct 31.
- Fass R, Quan SF, O'Connor GT, Ervin A, Iber C. Predictors of heartburn during sleep in a large prospective cohort study. Chest. 2005 May;127(5):1658-66. doi: 10.1378/chest.127.5.1658.
- Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S5-11.
- Jung HK, Choung RS, Talley NJ. Gastroesophageal reflux disease and sleep disorders: evidence for a causal link and therapeutic implications. J Neurogastroenterol Motil. 2010 Jan;16(1):22-9. doi: 10.5056/jnm.2010.16.1.22. Epub 2010 Jan 31.
- Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10.
- Fass R, Pulliam G, Johnson C, Garewal HS, Sampliner RE. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing. 2000 Mar;29(2):125-30. doi: 10.1093/ageing/29.2.125.
- Chait MM. Gastroesophageal reflux disease: Important considerations for the older patients. World J Gastrointest Endosc. 2010 Dec 16;2(12):388-96. doi: 10.4253/wjge.v2.i12.388.
- Saritas Yuksel E, Vaezi MF. New developments in extraesophageal reflux disease. Gastroenterol Hepatol (N Y). 2012 Sep;8(9):590-9.
- DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005 Jan;100(1):190-200. doi: 10.1111/j.1572-0241.2005.41217.x.
- Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV; American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008 Oct;135(4):1383-1391, 1391.e1-5. doi: 10.1053/j.gastro.2008.08.045. No abstract available.
- Dolder M, Tutuian R. Laboratory based investigations for diagnosing gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2010 Dec;24(6):787-98. doi: 10.1016/j.bpg.2010.10.005.
- Fass R, Achem SR, Harding S, Mittal RK, Quigley E. Review article: supra-oesophageal manifestations of gastro-oesophageal reflux disease and the role of night-time gastro-oesophageal reflux. Aliment Pharmacol Ther. 2004 Dec;20 Suppl 9:26-38. doi: 10.1111/j.1365-2036.2004.02253.x.
- Guare RO, Ferreira MC, Leite MF, Rodrigues JA, Lussi A, Santos MT. Dental erosion and salivary flow rate in cerebral palsy individuals with gastroesophageal reflux. J Oral Pathol Med. 2012 May;41(5):367-71. doi: 10.1111/j.1600-0714.2011.01112.x. Epub 2011 Nov 14.
- Wong WM, Lam KF, Cheng C, Hui WM, Xia HH, Lai KC, Hu WH, Huang JQ, Lam CL, Chan CK, Chan AO, Lam SK, Wong BC. Population based study of noncardiac chest pain in southern Chinese: prevalence, psychosocial factors and health care utilization. World J Gastroenterol. 2004 Mar 1;10(5):707-12. doi: 10.3748/wjg.v10.i5.707.
- Jansson C, Nordenstedt H, Wallander MA, Johansson S, Johnsen R, Hveem K, Lagergren J. A population-based study showing an association between gastroesophageal reflux disease and sleep problems. Clin Gastroenterol Hepatol. 2009 Sep;7(9):960-5. doi: 10.1016/j.cgh.2009.03.007. Epub 2009 Mar 13.
- Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agreus L, Jablonowski H, Zapardiel J. Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting. Health Qual Life Outcomes. 2009 Jul 2;7:60. doi: 10.1186/1477-7525-7-60.
- Ferrus JA, Zapardiel J, Sobreviela E; SYMPATHY I study group. Management of gastroesophageal reflux disease in primary care settings in Spain: SYMPATHY I study. Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1269-78. doi: 10.1097/MEG.0b013e32832a7d9b.
- Hungin AP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther. 2009 Aug 15;30(4):331-42. doi: 10.1111/j.1365-2036.2009.04047.x.
- Wallander MA, Johansson S, Ruigomez A, Garcia Rodriguez LA, Jones R. Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Fam Pract. 2007 Oct;24(5):403-11. doi: 10.1093/fampra/cmm050. Epub 2007 Aug 28.
- Kusano M, Kouzu T, Kawano T, Ohara S. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. J Gastroenterol. 2008;43(11):833-41. doi: 10.1007/s00535-008-2235-0. Epub 2008 Nov 18.
- Mody R, Bolge SC, Kannan H, Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol. 2009 Sep;7(9):953-9. doi: 10.1016/j.cgh.2009.04.005. Epub 2009 Apr 16.
- Marsicano JA, de Moura-Grec PG, Bonato RC, Sales-Peres Mde C, Sales-Peres A, Sales-Peres SH. Gastroesophageal reflux, dental erosion, and halitosis in epidemiological surveys: a systematic review. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):135-41. doi: 10.1097/MEG.0b013e32835ae8f7.
- Yoshikawa H, Furuta K, Ueno M, Egawa M, Yoshino A, Kondo S, Nariai Y, Ishibashi H, Kinoshita Y, Sekine J. Oral symptoms including dental erosion in gastroesophageal reflux disease are associated with decreased salivary flow volume and swallowing function. J Gastroenterol. 2012 Apr;47(4):412-20. doi: 10.1007/s00535-011-0515-6. Epub 2011 Dec 27.
- Correa MC, Lerco MM, Cunha Mde L, Henry MA. Salivary parameters and teeth erosions in patients with gastroesophageal reflux disease. Arq Gastroenterol. 2012 Jul-Sep;49(3):214-8. doi: 10.1590/s0004-28032012000300009.
- Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther. 2000 Apr;14(4):389-96. doi: 10.1046/j.1365-2036.2000.00733.x.
- Kao CH, Ho YJ, ChangLai SP, Liao KK. Evidence for decreased salivary function in patients with reflux esophagitis. Digestion. 1999;60(3):191-5. doi: 10.1159/000007658.
- Helm JF, Dodds WJ, Hogan WJ. Salivary response to esophageal acid in normal subjects and patients with reflux esophagitis. Gastroenterology. 1987 Dec;93(6):1393-7. doi: 10.1016/0016-5085(87)90270-8.
- Pope CE 2nd. Acid-reflux disorders. N Engl J Med. 1994 Sep 8;331(10):656-60. doi: 10.1056/NEJM199409083311007. No abstract available.
- Smith DJ, Joshipura K, Kent R, Taubman MA. Effect of age on immunoglobulin content and volume of human labial gland saliva. J Dent Res. 1992 Dec;71(12):1891-4. doi: 10.1177/00220345920710120701.
- Iorgulescu G. Saliva between normal and pathological. Important factors in determining systemic and oral health. J Med Life. 2009 Jul-Sep;2(3):303-7.
- Helm JF, Dodds WJ, Hogan WJ, Soergel KH, Egide MS, Wood CM. Acid neutralizing capacity of human saliva. Gastroenterology. 1982 Jul;83(1 Pt 1):69-74. No abstract available.
- http://www.moderndentistrymedia.com/jan_feb2012/walsh.pdf; Author: LJ Walsh; Title: Clinical aspects of salivary biology for the dental clinician. In ModerDentistryMedia
- Dutta SK, Agrawal K, Mahmoud MA. Modulation of salivation and heartburn in response to the site of acid infusion in the human oesophagus. Aliment Pharmacol Ther. 2010 Sep;32(6):795-800. doi: 10.1111/j.1365-2036.2010.04397.x.
- Haag S, Holtmann G. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. Clin Ther. 2010 Apr;32(4):678-90. doi: 10.1016/j.clinthera.2010.03.020.
- Armstrong D, Pare P, Pericak D, Pyzyk M; Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001 Oct;96(10):2849-57. doi: 10.1111/j.1572-0241.2001.4237_a.x.
- Vela MF. Medical treatments of GERD: the old and new. Gastroenterol Clin North Am. 2014 Mar;43(1):121-33. doi: 10.1016/j.gtc.2013.12.001. Epub 2013 Dec 31.
- Lee P, Burgess J. XyliMelts time-release adhering discs for night time oral dryness; Abstract accepted for presentation at the Oral Medicine Meeting, May 2009
- Kerr AR, Corby PM, Shah SS, Epler M, Fisch GS, Norman RG. Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc. 2010 Oct;141(10):1250-6. doi: 10.14219/jada.archive.2010.0053.
- Nwokediuko SC. Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol. 2012;2012:391631. doi: 10.5402/2012/391631. Epub 2012 Jul 11.
- Helm JF, Dodds WJ, Pelc LR, Palmer DW, Hogan WJ, Teeter BC. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med. 1984 Feb 2;310(5):284-8. doi: 10.1056/NEJM198402023100503.
- Printza A, Speletas M, Triaridis S, Wilson J. Is pepsin detected in the saliva of patients who experience pharyngeal reflux? Hippokratia. 2007 Jul;11(3):145-9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GERD
-
Baylor Research InstituteNot yet recruiting
-
Ohio State UniversityCompleted
-
EndoStim Inc.TerminatedGERDDenmark, Netherlands, Germany, Austria, United Kingdom, Argentina, Mexico
-
Chong Kun Dang PharmaceuticalCompleted
-
Chong Kun Dang PharmaceuticalCompletedGERDKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedGERDKorea, Republic of
-
Yooyoung Pharmaceutical Co., Ltd.Completed
-
Chong Kun Dang PharmaceuticalCompletedGERDKorea, Republic of
-
Dr. Reddy's Laboratories LimitedCompleted
Clinical Trials on Xylitol
-
Cairo UniversityUnknown
-
University Hospital, Basel, SwitzerlandCompletedPhysiological Satiation MechanismsSwitzerland
-
Hadassah Medical OrganizationUnknown
-
Children's Hospital Medical Center, CincinnatiTerminatedAllogeneic Hematopoietic Cell TransplantationUnited States
-
Baylor College of MedicineCompletedPreterm Birth | Periodontal Disease | Caries, DentalUnited States
-
Rambam Health Care CampusCarmel Medical CenterCompleted
-
Boston Children's HospitalNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAcute Otitis MediaUnited States
-
University of WashingtonCompleted
-
University Hospital, Basel, SwitzerlandCompleted
-
Università degli Studi di SassariUniversity of MilanCompletedPeriodontal Diseases | Dental CariesItaly